Pyridazines as inhibitors of the enzyme conversion of interleukin-1beta the.

Discloses compounds of the formula IY pharmacologically acceptable salts thereof, wherein R is halogen, oxygen connected to a leaving group including aromatic ether, aromatic ester, alkyl sulfonate, arylsulfonate, alkyl phosphonate, aryl phosphonate, alkyl phosphate or aryl phosphate; R2 IS OR5, NH (CHR5) MCOOR5, NH (CHR 5) MCON (R5) R6 or NR5R6 NH (CHR 5) NOH; R3 is H or alkyl; R4 is H, substituted aryl or unsubstituted heteroaryl or alkyl; R5 and R6 are independently H, lower alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl or lower cycloalkyl; M = 1-6; YN = 2-6. Also presented the pharmaceutical compositions containing the compounds; And a method for inhibiting the protease activity of interleukin 1- (BETA) in a mammal using the compounds and compositions of the invention.